Future Medicine Ltd has announced that its journal Nanomedicine (ISSN: 1743-5889) has been selected for coverage in ISI(reg) services after the publication of only five issues.
"We at Nanomedicine are delighted that the journal has been accepted for coverage by ISI after only one year. This speaks not only to the importance of the field, but also to the high quality of the articles and features published to date in Nanomedicine. We also recognize that the outstanding scientists on our editorial advisory board played a large role in the rapid development of Nanomedicine, and we look forward to continuing fruitful interactions with the board and with all the authors who choose to publish their excellent work in Nanomedicine.", says Professor Charles R Martin, Director of the Center for Research at the Bio/Nano Interface and Colonel Allen R and Margaret G Crow Professor of Chemistry, University of Florida (FL, USA), and Senior Editor of the journal.
Kostas Kostarelos, Centre for Drug Delivery Research, University of London (UK) and also Senior Editor of the journal commented; "Recognition by the Institute of Scientific Information is considered by all of us in the journal as an indication that nanomedicine is entering the mainstream of scientific advance and that the journal Nanomedicine is at the forefront of this field. We are determined to grow stronger as a journal and contribute to medical practice as a whole."
Topics covered in the first year of publication by Nanomedicine include basic research and theoretical applications of nanomedical technology, potential medical applications and therapeutic applications of nanotechnology advances, nanomedical tools in gene therapy, drug delivery and commercialization, funding, economics and ethics of nanomedical technology.
Morag Robertson, Editor at Future Medicine said; "We are delighted that Nanomedicine has been accepted by Thomson ISI at this early stage of the journal's development. The field of nanotechnology and its medical applications has become one of the hottest areas in science today and the launch of Nanomedicine has been greeted with huge interest. We would like to thank the journal's Senior Editors, Professor Charles Martin and Dr Kostas Kostarelos, for their encouragement as well as our outstanding Editorial Board for their input and guidance thus far. We anticipate further success with Nanomedicine as we move forward."
The Senior Editors and Future Medicine Ltd aim to make Nanomedicine the main forum in which the challenges and advances in nanotechnology research related to medicine are addressed. In upcoming years, the field promises much - Nanomedicine will be there to highlight the main advances and therapeutic possibilities for clinicians and researchers alike and will provide an avenue for debate of controversial issues.
Nanomedicine Accepted for Coverage in MEDLINE
Elsevier, the world's leading scientific, technical and medical publisher has announced that its journal, Nanomedicine: Nanotechnology, Biology and Medicine has been selected for inclusion in MEDLINE®. Maintained by the U.S. National Library of Medicine®, MEDLINE (Medical Literature Analysis and Retrieval System Online) is the premier bibliographic database containing approximately 13 million references to journal articles in life sciences with a concentration on biomedicine.
Nanomedicine Editor-in-Chief, Chiming Wei, MD, PhD, Department of Surgery, Johns Hopkins University School of Medicine, commented, "The entire Editorial Board and I are extremely pleased that Nanomedicine is being added to the MEDLINE journal collection so soon after its launch in March 2005 in recognition of its scientific merit and contribution to the field. Inclusion in this prominent database will help investigators throughout the world more easily locate articles published in Nanomedicine.
Nanomedicine: Nanotechnology, Biology and Medicine (nanomedjournal), the Official Journal of the American Academy of Nanomedicine (AANM), is an international, peer-reviewed journal published quarterly. Nanomedicine publishes basic, clinical and engineering research in the innovative field of nanomedicine. Article categories include diagnostic, experimental, clinical, engineering, pharmacological and basic nanomedicine. Nanomedicine provides the latest information in this rapidly developing field, covering both research advancements and clinical applications. The Journal publishes original clinical and investigative studies, state-of-the-art papers, reports on new equipment and techniques, review articles and more.
Nanomedicine, an offshoot of nanotechnology, refers to highly specific medical intervention at the molecular scale for curing disease or repairing damaged tissues, such as bone, muscle or nerve. A nanometer is one-billionth of a meter, too small to be seen with a conventional lab microscope. It is at this size scale - about 100 nanometers or less - that biological molecules and structures inside living cells operate.
The National Library of Medicine MEDLINE selection process is managed by an advisory committee, the Literature Selection Technical Review Committee, composed of authorities knowledgeable in the field of biomedicine, such as physicians, researchers, educators, editors, health science librarians and historians, to review and recommend the journal titles NLM should index. With inclusion in MEDLINE, citations, abstracts and indexing terms for articles published in Nanomedicine will be available online in the U.S. and throughout the world back to Volume 1/Issue 1. MEDLINE is searchable for free using PubMed at pubmed.
Elsevier, a world-leading medical and scientific publisher, brings the full support of its global organization to the journal. It is recognized for its numerous long-standing and successful society-publishing partnerships, as well as excellence in all aspects of the publishing process. ScienceDirect (sciencedirect), Elsevier's world-class electronic platform with over 16 million users, provides online access to the full text of Nanomedicine to institutional subscribers. Members of the affiliated society and individual subscribers are able to access the journal via nanomedjournal.
ABOUT FUTURE SCIENCE GROUP
Future Science Group Ltd, based in London has developed an innovative publishing portfolio to reflect post-genomic medicine. The sequencing of the human genome was a colossal milestone in the evolution of healthcare, with repercussions for all those involved in the healthcare chain. Through its imprints, Future Medicine, Future Drugs and Future Biology, the Future Science Group provides healthcare practitioners and research professionals with a unique source of objective, cutting-edge information on exciting trends emerging in the light of these advances. Our flagship title Pharmacogenomics has evolved to become a leading source of commentary and analysis from international opinion leaders. Momentum toward an individualized approach to medicine is increasing as the value of linking diagnostic and therapeutic approaches becomes ever clearer.
For more information please access future-drugs, futuremedicine and future-biology
ABOUT THE AMERICAN ACADEMY OF NANOMEDICINE
The American Academy of Nanomedicine (aananomed) is a forum to exchange ideas, communicate new findings and encourage collaboration among the diverse disciplines represented in Nanomedicine. Membership in AANM includes a subscription to Nanomedicine: Nanotechnology, Biology, and Medicine.
ABOUT ELSEVIER
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. Working in partnership with the global science and health communities, Elsevier's 7,000 employees in over 70 offices worldwide publish more than 2,000 journals and 1,900 new books per year, in addition to offering a suite of innovative electronic products, such as ScienceDirect, MD Consult, Scopus, bibliographic databases, and online reference works.
Elsevier is a global business headquartered in Amsterdam, The Netherlands and has offices worldwide. Elsevier is part of Reed Elsevier Group plc, a world-leading publisher and information provider. Operating in the science and medical, legal, education and business-to-business sectors, Reed Elsevier provides high-quality and flexible information solutions to users, with increasing emphasis on the Internet as a means of delivery. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Комментариев нет:
Отправить комментарий